Preparation of doxorubicin-loaded stealth liposomes modified with RGD mimetic and cellular association in vitro

Yaoxue Xuebao

Volumn 40, Issue 12, 2005, Pages 1085-1090

  Xiong, Xiao Bing ^a   Huang, Yue ^b   Lü, Wan Liang ^a   Zhang, Xuan ^a   Zhang, Hua ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Doxorubicin; Drug delivery; Integrin; RGD; Stealth liposomes

Indexed keywords

1,2 DISTEAROYLPHOSPHATIDYLETHANOLAMINE; 1,2-DISTEAROYLPHOSPHATIDYLETHANOLAMINE; ANTINEOPLASTIC ANTIBIOTIC; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; DOXORUBICIN; DRUG CARRIER; LIPOSOME; MACROGOL DERIVATIVE; OLIGOPEPTIDE; PHOSPHATIDYLETHANOLAMINE;

ANIMAL; ARTICLE; CELL ADHESION; CELL NUCLEUS; DRUG DELIVERY SYSTEM; EXPERIMENTAL MELANOMA; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL ADHESION; CELL LINE, TUMOR; CELL NUCLEUS; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MELANOMA, EXPERIMENTAL; OLIGOPEPTIDES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS;

EID: 31644441966     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Yuan F, Leunig M, Huang SK, et al. Microvascular permeability and interstitial penetration of sterically stabilized ( stealth ) liposomes in a human tumor xenograft [J]. Cancer Res, 1994,54(13):3352-3356.
2. Geh B, Winterhalter M, Frederik P, et al. Stealth liposomes; from theory to product [J]. Adv Drug Deliv Rev, 1997,24(2);165-177.
3. Lopes de Menezes DE, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma [J]. Cancer Res, 1998,58 (15):3320-3330.
4. Moreira JN, Caspar R, Allen TM. Targeting stealth liposomes in a murine model of human small cell lung cancer [J]. Boichim Biophys Acta, 2001,1515(2): 167-176.
5. Gabizon A, Shmeeda H, Horowitz AT, et al. Tumor cell targeting of liposome- entrapped drugs with phospholipid-anchored folic acid-PEG conjugates [J]. Adv Drug Deliv Rev, 2004,56(8):1177-1192.
6. Ruoslahti E. RGD and other recognition sequences for integrins [J]. Annu Rev Cell Dev Biol, 1996,12:697-715.
7. Matsumoto T, Numata M, Anada T, et al. Chemically modified polysaccharide schizophyllan for antisense oligonucleotides delivery to enhance the cellular uptake efficiency [J]. Biochim Biophys Acta, 2004,1670(2): 91-104.
8. Kurohane K, Namba Y, Oku N. Liposomes modified with a synthetic Arg-Gly-Asp mimetic inhibit lung metastasis of B16BL6 melanoma cells [J]. Life Sci, 2000,68(3): 273-281.
9. Haran G, Cohen R, Bar LK, et al. Transmembrane ammonium sulfate gradient in liposomes produce efficient and stable entrapment of amphipathic weak bases [J]. Biochim Biophys Acta, 1993,1151(2):201-215.
10. Zhang XB, Jin YG, Xie Y, et al. Effect of RMP-7 and its derivatives on the transportation of liposomes into the brain [J]. Acta Pharm Sin, 2003,38 (11):867-870.
11. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro [J]. Biochim Biophys Acta, 1995,1233(2):134-144.
12. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethyleneglycol coated liposomes [J]. Cancer Res, 1994,54(4): 987-992.
13. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs [J]. Cancer Res, 2002,62(24):7190-7194.
14. Hart IR, Birch M, Marshall JF. Cell adhesion receptor expression during melanoma progression and metastasis [J]. Cancer Metastasis Rev, 1991,10(2):115-128.